Mallinckrodt and Endo Pharmaceuticals are uniting, intending to be listed on the New York Stock Exchange. TruBit Collaborates with Morpho to Introduce DeFi Unearned Revenue in Latin America
**Main Aspects:**
* The two drugmakers revealed on Thursday that Mallinckrodt, headquartered in Dublin, will procure its smaller competitor, Endo, intending to list the united entity on the NYSE.
* The fresh entity is projected to possess an enterprise worth of $6.7 billion.
* Both drug firms have surfaced from insolvency in recent times and have been confronting legal actions concerning their manufacturing of opioid medications.
According to the agreement’s stipulations, Endo stockholders will obtain $80 million in currency and possess 49.9% of the consolidated entity. Mallinckrodt will function as the parent organization, with its stockholders regulating 50.1% of the equities. The arrangement assesses the consolidated entity at $6.7 billion.
Following the consolidation, the firms intend to merge their non-brand medication operations with Endo’s sterile injectable operation and subsequently divest that segment. The consolidation, which has garnered approval from both executive boards, is anticipated to conclude in the latter portion of 2025.
Endo’s acting Chief Executive Officer, Scott Hirsch, articulated that the consolidation with Mallinckrodt, succeeded by the segregation of the consolidated sterile injectables and non-brand operations, will furnish a distinct prospect for stockholders and generate substantial worth.
